Also Known As
Macrilen · AEZS-130 · EP-01572
Overview
Macimorelin is an orally active ghrelin receptor agonist approved by the FDA for diagnosis of adult growth hormone deficiency (AGHD). It stimulates GH release and is used as a diagnostic tool in clinical settings.
Mechanism of Action
Agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). Oral bioavailability enables convenient diagnostic testing. Metabolized by CYP3A4.
Quick Reference
Notes
FDA approved for AGHD diagnosis. GH peak occurs 30-90 minutes post-dose. Not for therapeutic use.
Dosing Protocol
Pharmacokinetics
Administration
Special Instructions
FDA approved for GH deficiency DIAGNOSIS only. Single dose test - GH measured 30, 45, 60, and 90 minutes post-dose. Not for repeated therapeutic use.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!